NAD+ in Cellular Energy and Ageing Research: What the Science Shows

What is NAD+?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in all living cells. It functions as a redox carrier in metabolic reactions, accepting and donating electrons in processes including glycolysis, the citric acid cycle, and oxidative phosphorylation. NAD+ is essential for ATP production and cellular energy homeostasis.

Beyond its role in bioenergetics, NAD+ serves as a substrate for several enzyme classes that regulate gene expression, DNA repair, and cellular stress responses. These include sirtuins (class III histone deacetylases), poly(ADP-ribose) polymerases (PARPs), and cyclic ADP-ribose synthases (Verdin, 2015).

Molecular Formula: C21H27N7O14P2

CAS Number: 53-84-9

Molecular Weight: 663.43 Da

NAD+ Decline with Age

A key finding driving NAD+ research is the consistent observation that cellular NAD+ levels decline significantly with age across multiple tissues and species. In rodent models, NAD+ concentrations fall by approximately 50% between young adulthood and middle age in tissues including skeletal muscle, liver, and brain. Comparable trends have been documented in human tissue samples (Yoshino, Baur, and Imai, 2018).

This age-related decline is thought to result from three converging factors: reduced biosynthesis via the salvage pathway, increased NAD+ consumption by PARPs (which are activated by accumulating DNA damage), and reduced expression of the rate-limiting biosynthetic enzyme NAMPT (Imai and Guarente, 2014).

Sirtuins and the NAD+ Connection

Sirtuins (SIRT1-7 in mammals) are NAD+-dependent deacylases that regulate numerous cellular processes, including gene silencing, mitochondrial biogenesis, fatty acid oxidation, and inflammatory signalling. Critically, sirtuin activity is directly dependent on NAD+ availability: as NAD+ falls, sirtuin function is impaired (Imai and Guarente, 2014).

Sirtuin research has linked NAD+ levels to several hallmarks of ageing, including epigenetic dysregulation, mitochondrial dysfunction, and impaired DNA repair capacity. Restoring NAD+ in aged animal models has been shown to reactivate sirtuin activity and partially reverse age-related phenotypes in muscle, liver, and metabolic tissue (Rajman, Chwalek, and Sinclair, 2018).

Mitochondrial Function and Nuclear Communication

A pivotal study by Gomes et al. (2013) proposed a mechanism linking NAD+ decline to mitochondrial dysfunction. As NAD+ falls, SIRT1 activity decreases. This impairs the function of HIF-1 alpha (hypoxia-inducible factor) regulatory pathways, leading to a pseudohypoxic state in which nuclear-mitochondrial communication is disrupted. The result is impaired mitochondrial biogenesis and reduced oxidative capacity in muscle tissue.

Supplementation with NAD+ precursors (NMN and NR) in aged mice restored NAD+ levels, re-established nuclear-mitochondrial signalling, and improved mitochondrial function (Gomes et al., 2013).

NAD+ and DNA Repair

PARPs are enzymes that use NAD+ as a substrate to synthesise poly(ADP-ribose) chains at DNA damage sites, coordinating the DNA damage response. With ageing and accumulated DNA damage, PARP activity increases chronically, accelerating NAD+ depletion. This creates a vicious cycle: reduced NAD+ impairs sirtuin-mediated DNA repair, while increased PARP activation further depletes NAD+ (Rajman, Chwalek, and Sinclair, 2018).

Research in Metabolic Models

Beyond ageing, NAD+ research has examined metabolic applications. Studies in diet-induced obese rodent models have reported that NAD+ precursor supplementation improves insulin sensitivity, reduces hepatic fat accumulation, and increases energy expenditure via SIRT1/SIRT3-mediated pathways. These effects appear to require sufficient NAD+ availability and are attenuated when sirtuin expression is knocked out (Canto et al., 2012).

NAD+ Precursors in Research

Direct NAD+ administration has limited cellular bioavailability due to poor membrane permeability. Research studies typically use NAD+ precursors (NMN, NR) or supply NAD+ directly in cell culture systems. Our NAD+ 100mg is supplied as a lyophilised powder for research use in in-vitro systems where direct NAD+ exposure is the experimental variable.

Research Summary

Key References

1. Verdin E. "NAD+ in Aging, Metabolism, and Neurodegeneration." *Science.* 2015;350(6265):1208-1213.

2. Imai SI, Guarente L. "NAD+ and Sirtuins in Aging and Disease." *Trends in Cell Biology.* 2014;24(8):464-471.

3. Rajman L, Chwalek K, Sinclair DA. "Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence." *Cell Metabolism.* 2018;27(3):529-547.

4. Yoshino J, Baur JA, Imai SI. "NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR." *Cell Metabolism.* 2018;27(3):513-528.

5. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA. "Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging." *Cell.* 2013;155(7):1624-1638.

6. Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, Gademann K, Rinsch C, Schoonjans K, Sauve AA, Auwerx J. "The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity." *Cell Metabolism.* 2012;15(6):838-847.

Disclaimer: All information is based on published preclinical and in-vitro research literature and is provided for educational purposes only. NAD+ is sold strictly for in-vitro laboratory and research purposes. Not medical advice.